InsidersTradesSigma
Track the Werewolf Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Werewolf Therapeutics, Inc. has published 83 reports. Market capitalisation: €45.8m. The latest transaction was reported on 8 July 2026 (Cession). Among the most active insiders: EVNIN LUKE. The full history is accessible without an account.
83
Insider Decl.
n/a
Thresholds
€7m
3 ops.
Buy Volume
€2m
50 ops.
Sell Volume
27Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 July 2026
Declarations83 total
35,770 shares@ US$0.320.069% mcap4.1% of flowCommon StockSEC:0001134657-26-000020:0
107,429 shares@ US$0.310.20% mcap11.8% of flowCommon StockSEC:0001134657-26-000020:1
15,341 shares@ US$0.34040.028% mcap100.0% of flowCommonSEC144:0001628280-26-047365
3,332 shares@ US$0.34040.0061% mcap100.0% of flowCommonSEC144:0001628280-26-047366
6,459 shares@ US$0.34040.012% mcap100.0% of flowCommonSEC144:0001628280-26-047362
96,873 shares@ US$0.34040.18% mcap93.8% of flowCommonSEC144:0001628280-26-047360
21,194 shares@ US$0.34040.039% mcap100.0% of flowCommonSEC144:0001628280-26-047367
80,142 shares@ US$0.34040.15% mcap100.0% of flowCommonSEC144:0001628280-26-047364
16,830 shares@ US$0.3230.029% mcap51.0% of flowCommonSEC144:0001628280-26-046085
3,657 shares@ US$0.3230.0064% mcap51.0% of flowCommonSEC144:0001628280-26-046086
7,087 shares@ US$0.3230.012% mcap51.0% of flowCommonSEC144:0001628280-26-046083
106,262 shares@ US$0.3230.19% mcap4.0% of flowCommonSEC144:0001628280-26-046082
23,248 shares@ US$0.3230.041% mcap51.0% of flowCommonSEC144:0001628280-26-046087
87,916 shares@ US$0.3230.15% mcap51.0% of flowCommonSEC144:0001628280-26-046084
157,084 sharesCommon StockSEC:0001134657-26-000019:0
76,928 sharesCommon StockSEC:0001134657-26-000018:0
20,072 shares@ US$0.440.042% mcap10.1% of flowCommon StockSEC:0001134657-26-000017:0
24,946 shares@ US$0.400.047% mcap11.4% of flowCommon StockSEC:0001134657-26-000017:1
60,547 sharesCommon StockSEC:0001134657-26-000017:2
27,698 shares@ US$0.460.050% mcap18.5% of flowCommon StockSEC:0001134657-26-000015:1
32,556 shares@ US$0.450.058% mcap21.3% of flowCommon StockSEC:0001134657-26-000015:2
80,852 shares@ US$0.480.15% mcap56.2% of flowCommon StockSEC:0001134657-26-000015:0
53,940 shares@ US$0.850.27% mcap18.9% of flowCommon StockSEC:0001134657-26-000007:0
95,412 shares@ US$0.730.41% mcap28.7% of flowCommon StockSEC:0001134657-26-000007:1
56,559 shares@ US$0.690.23% mcap16.1% of flowCommon StockSEC:0001134657-26-000007:2
25 of 83 declarations
关于 Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. (股票代码: HOWL) 是一家在美国纳斯达克市场上市的美国生物制药公司，总部位于马萨诸塞州沃特敦。该公司成立于2017年，并于2021年4月上市，专注于围绕条件激活疗法构建差异化的免疫肿瘤学策略。其核心投资理念直截了当：在降低历史上限制细胞因子疗法的全身毒性的同时，努力保持免疫刺激药物的抗肿瘤能力。 故事的核心是Werewolf专有的PREDATOR®平台。该平台旨在创建在周围组织中基本不活跃，并在肿瘤微环境中优先激活的分子。这种方法支撑了公司的INDUKINE™项目，旨在在最需要的地方释放免疫活性，同时限制脱靶暴露。Werewolf的两个主要临床阶段候选药物是WTX-124（一种条件激活的IL-2 INDUKINE分子）和WTX-330（一种条件激活的IL-12 INDUKINE分子）。两者主要针对实体瘤开发，公司力求证明其在疗效和耐受性方面优于传统促炎免疫疗法。 除了细胞因子，Werewolf还强调了其INDUCE™ T细胞衔接器平台，该平台拓宽了技术基础，并可能扩大其管线选择性。竞争定位意义重大但充满挑战：公司在肿瘤生物技术创新者和大型制药集团的拥挤领域中运营，这些公司正在寻求下一代免疫疗法、双特异性抗体和细胞衔接方法。Werewolf的差异化在于其掩蔽/激活化学以及比传统细胞因子平台更精确地调节免疫刺激的雄心。与此同时，公司仍处于开发阶段的生物技术公司，因此估值对临床结果、监管进展和融资条件高度敏感。 最近的公司更新尤为重要。在2025年和2026年，Werewolf报告了WTX-124和WTX-330的管线进展，包括额外的临床更新以及对INDUCE平台和合作机会的重新强调。2026年3月，管理层披露正在探索战略替代方案以最大化股东价值，包括可能的出售、合并、资产交易、许可协议或合作。公司2026年第一季度的备案文件还显示了一项重大重组，包括裁员64%，这突显了公司为节省资本并将资源与战略审查保持一致所做的努力。因此，对于投资者而言，HOWL最好被视为一家创新但高风险的临床阶段生物技术公司，其价值创造与临床验证和潜在的战略选择性相关。
